Photo by William A. Paxton, 2012 / CC BY 3.0
Vaneltix Pharma of New Brunswick, New Jersey, and Hyloris Pharmaceuticals of Liège, Belgium, said November 9 that their experimental bladder-pain treatment Alenura met the main goal of a Phase 2 U.S. trial. The companies reported better pain relief than placebo and either ingredient given alone, but did not disclose the size of the benefit or adverse-event results. Alenura remains in clinical development, not an FDA-approved treatment.
The companies’ release, issued at 7 a.m. Eastern, describes a randomized, double-blind, four-arm study of 153 adults with interstitial cystitis/bladder pain syndrome, or IC/BPS, during acute episodes of moderate-to-severe bladder pain. Participants received a single treatment placed directly into the bladder: Alenura, placebo, alkalinized lidocaine or heparin alone. The design tests whether combining the ingredients adds benefit beyond either one by itself.
The main measure was SPID-12, the sum of changes in bladder-pain intensity over the 12 hours after treatment. The trial registry describes pain ratings on a zero-to-10 scale, where zero is no pain and 10 is the worst imaginable pain. The companies said Alenura was statistically superior to all three comparators, with every reported p-value below 0.01.
That statistical result is not a numerical description of how much better patients felt. The announcement provides neither the treatment differences nor confidence intervals, and gives no actual participant count for each arm. Without those figures, readers cannot assess the size and precision of the reported advantage or how consistently patients experienced it.
Pain-relief assessments at 24 hours also favored Alenura, the companies said, alongside supportive patient-reported symptom improvements. They did not provide numerical 24-hour results. A single-dose study measured over hours should not be read as proof of lasting control of a chronic condition, prevention of future flares or a cure.
Alenura combines alkalinized lidocaine, a local anesthetic, with heparin in a ready-to-use bladder instillation. The companies describe lidocaine as intended to provide rapid relief and heparin as intended to support the bladder’s protective lining and potentially sustain relief. Those descriptions explain the development rationale; they do not establish the mechanism or clinical benefit independently of the trial data.
IC/BPS can involve recurring bladder and pelvic pain or discomfort, often alongside urinary urgency and frequency. For patients, the importance of this announcement is the possibility of another treatment for painful flares, rather than an available new prescription today. For the developers, superiority to both individual components supports their case for continuing work on the combination, while leaving the remaining evidence and regulatory review ahead.
The public registry still lists estimated enrollment of 120 and a recruiting status, while the new release reports 153 adults evaluated. Its planned arm counts are anticipated figures, not confirmed final results. The registry supports the study design but has not been reconciled with the company’s latest participant total in the record reviewed for this report. The release does not identify a peer-reviewed paper or provide the adverse-event findings needed to assess tolerability.
Vaneltix and Hyloris said additional development work is continuing to support preparations for a U.S. New Drug Application under the 505(b)(2) pathway, subject to the remaining clinical and regulatory requirements. They announced no submission date. Preparing an application is different from filing it, and filing would not itself mean FDA approval. The next useful disclosures are the full efficacy results, safety findings, final arm sizes and a clearer regulatory timetable.
JBizNews Desk | New Brunswick, New Jersey / Liège, Belgium
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
